Additionally, novel oral aminomethy-lthiophene-based compounds, acting as dual LOX/LOXL2 inhibitors, have emerged as promising candidates due to their excellent bioavailability and anti-tumor activity 183. Here, LOXL2 is linked to neoplasm.